The Cost-Effectiveness of HPV Vaccination for Adults Aged 30 to 45 Years
This study evaluated the cost-effectiveness of extending the upper age limit of human papillomavirus (HPV) vaccination to age 30 to 45 years using two independent HPV microsimulation models and found that vaccinating in this age group was not cost-effective.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.